Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minnelide in Advanced Solid Tumors
NCT03129139Phase 1Recruiting
- Sponsor
- Minneamrita Therapeutics LLC
- Start
- Oct 2017
- Primary completion
- Jun 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of minnelide in solid tumor (advanced stage), gastric cancer (GC), breast cancer and 3 more (3 arms), sponsored by Minneamrita Therapeutics LLC. Primary endpoints: Number of Participants With Treatment-Related Adverse Events at 24 months and Anti-tumor activity at 24 months. Started Oct 2017; status: recruiting.
02
Drugs
minnelide
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)breast cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03129139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129139.